Linking EEG brain activity and pathology in Lewy body disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, retrospective analysis of adults from the Alpha-Lewy-MA cohort who underwent RT-QuIC testing and a standard EEG at the University Hospital of Strasbourg between 2012 and 2020. Researchers will analyze EEG dynamics to see if characteristic abnormalities correlate with RT-QuIC results and neuropathological features of Lewy body disease. The goal is to confirm that observed EEG phenomena are linked to disease pathophysiology and to more precisely characterize those brain dynamics. No new interventions are administered; the work uses existing clinical and electrophysiological data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult subjects (≥18 years old).
* Subject who participated in the Alpha-Lewy-MA cohort and underwent RT-QuIC analysis.
* Subject who underwent a standard EEG examination at HUS between January 1, 2012, and January 1, 2020.

Exclusion Criteria:

\- Subject who expressed opposition to participating in the study.

Where it's running

• Service de psychiatrie de la personne âgée - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Ludovic DORMEGNY-JEANJEAN, MD
• Email: ludovic.jeanjean@chru-strasbourg.fr
• Phone: 33 3 88 11 69 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A look at why Lewy body conditions cause visual hallucinations

  This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.

  Recruiting NYU Langone Health · New York, New York · NCT07849413

• Donanemab in Early Cognitive Decline with Lewy Body Features (TRAILBLAZER-ALZ 7)

  This trial tests donanemab versus placebo to see if it can slow thinking and daily-function decline in people with early cognitive decline and Lewy body disease features.

  Recruiting at 47 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 71 other locations · NCT07589595

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• Swedish BioFINDER Sleep program for early Parkinson's disease and REM sleep behavior disorder

  This project will test whether sleep studies, brain and heart imaging, and fluid biomarkers can identify synuclein pathology and help predict progression in people with early Parkinson's disease or idiopathic REM sleep behavior disorder.

  Recruiting Skane University Hospital · Malmö · NCT07533799

• Using brain stimulation and digital training to improve cognitive function in older adults

  This study is testing whether a combination of brain stimulation and digital training can help improve thinking skills in older adults with Mild Cognitive Impairment and Alzheimer's Disease.

  Recruiting Universidade Federal do Rio de Janeiro · Rio de Janeiro, Rio de Janeiro · NCT06733714

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.